Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications-Reference-Cited by-同舟云学术

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Published:2021-03-11 Issue:4 Volume:21 Page:527-540
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Godman Brian¹²³⁴^ORCID,Hill Andrew⁵,Simoens Steven⁶^ORCID,Selke Gisbert⁷^ORCID,Selke Krulichová Iva⁸^ORCID,Zampirolli Dias Carolina⁹¹⁰,Martin Antony P¹¹¹²^ORCID,Oortwijn Wija¹³,Timoney Angela²¹⁴,Gustafsson Lars L¹,Voncina Luka¹⁵^ORCID,Kwon Hye-Young²¹⁶,Gulbinovic Jolanta¹⁷,Gotham Dzintars¹⁸,Wale Janet¹⁹,Cristina Da Silva Wânia⁹²⁰^ORCID,Bochenek Tomasz²¹,Allocati Eleonora²²,Kurdi Amanj²³²³^ORCID,Ogunleye Olayinka O.²⁴²⁵^ORCID,Meyer Johanna C³^ORCID,Hoxha Iris²⁶,Malaj Admir²⁷,Hierländer Christian²⁸,Sauermann Robert²⁸,Hamelinck Wouter²⁹,Petrova Guenka³⁰^ORCID,Laius Ott³¹,Langner Irene⁷,Yfantopoulos John³²^ORCID,Joppi Roberta³³,Jakupi Arianit³⁴^ORCID,Greiciute-Kuprijanov Ieva³⁵,Vella Bonanno Patricia²,Piepenbrink Jf (Hans)³⁶,de Valk Vincent³⁶,Wladysiuk Magdalene³⁷,Marković-Peković Vanda³⁸^ORCID,Mardare Ileana³⁹^ORCID,Fürst Jurij⁴⁰,Tomek Dominik⁴¹^ORCID,Obach Cortadellas Mercè⁴²^ORCID,Zara Corinne⁴²^ORCID,Pontes Caridad⁴²⁴³^ORCID,McTaggart Stuart⁴⁴,Laba Tracey-Lea⁴⁵,Melien Øyvind⁴⁶,Wong-Rieger Durhane⁴⁷,Bae SeungJin⁴⁸^ORCID,Hill Ruaraidh⁴⁹^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden

2. Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

3. Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

4. School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

5. Institute of Translational Medicine, University of Liverpool, UK

6. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium

7. Wissenschaftliches Institut Der AOK (WIdO), Berlin, Germany

8. Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec, Králové, Czech Republic

9. Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil

10. SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil

11. Faculty of Health and Life Sciences, Liverpool, UK

12. QC Medica, Sim Balk Lane, York UK

13. Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

14. NHS Lothian, Edinburgh, UK

15. Faculty of Health Studies, Rijeka, Croatia

16. Division of Biology & Public Health, Mokwon University, Daejeon, Korea

17. Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

18. Independent Researcher, Boston, MA, United States

19. Independent Consumer Advocate, Brunswick, Victoria, Australia

20. Data and Knowledge Integration Center for Health(CIDACS), Fundação Oswaldo Cruz (FIOCRUZ)/ Salvador, Bahia, Brazil

21. Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

22. Istituto Di Ricerche Farmacologiche ‘Mario Negri’ IRCCS, Milan, Italy

23. Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

24. Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria

25. Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria

26. Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania

27. University of Medicine, Tirana, Albania

28. Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, Austria

29. Statistics Department, Bruxelles, Belgium

30. Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria

31. State Agency of Medicines, Tartu, Estonia

32. School of National and Kapodistrian University of Athens Athens Greece

33. Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy

34. Faculty of Pharmacy, UBT – Higher Education Institution, Prishtina, Kosovo

35. Department of Pharmacy, Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania

36. National Health Care Institute (ZIN), XH, Diemen, Netherlands

37. HTA Consulting, Cracow, Poland

38. Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina

39. Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, Romania

40. Health Insurance Institute, Ljubljana, Slovenia

41. Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia

42. Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain

43. Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma De Barcelona, Barcelona, Spain

44. Public Health Scotland, Edinburgh, UK

45. Centre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, Sydney, NSW

46. Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway

47. Health Data Science, Institute of Population Health, Liverpool, Canadian Organization for Rare Disorders, Toronto, Ontario, Canada

48. College of Pharmacy, Ewha Woman’s University, Seoul, South Korea

49. Health Data Science, Institute of Population Health Liverpool Reviews and Implementation Group, Whelan Building, University of Liverpool, Liverpool, UK

Funder

research and no assistance with the write-up

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1884546

Reference143 articles.

1. IQVIA. The Global Use of Medicine in 2019 and Outlook to 2023 - Forecasts and Areas to Watch. 2019. [cited 2020 Dec 10]. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf.

2. Waters R, Urquhart L. EvaluatePharma® World Preview 2019, Outlook to 2024. 2019. [cited 2020 Dec10]. Available at URL: https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf.

3. IQVIA Institute for Human Data Science. Global Oncology Trends 2018. [cited 2020 Dec9]. Available at URL: https://www.iqvia.com/institute/reports/global-oncology-trends-2018.

4. What Happens when the Cost of Cancer Care Becomes Unsustainable?

5. IMS Institute for Healthcare Informatics. Global Oncology Trend Report. A Review of 2015 and Outlook to 2020. June 2016. [cited 2020 Dec 11]. Available at URL: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®);Value in Health;2024-08

2. Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma;European Journal of Haematology;2024-06-10

3. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands;Value in Health;2024-06

4. Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024;Journal of Pharmaceutical Policy and Practice;2024-04-12

5. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability;BMJ Open;2024-04